Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Memantine
Drug ID BADD_D01378
Description Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's disease [A1639]. Memantine blocks the effects of glutamate, a neurotransmitter in the brain that leads to neuronal excitability and excessive stimulation in Alzheimer's Disease [T556]. In 2010, it was estimated that 36 million people worldwide live with Alzheimer's Disease. In 2013, this number increased to 44 million. Almost doubling every 20 years, the prevalence of Alzheimer's Disease is predicted to reach 66 million by 2030 and to 115 million by 2050 [F4366]. In December 2013, the G8 dementia summit concluded that dementia should be considered a global priority with the objective of developing a cure or a disease-modifying therapy by the year 2025 [L5953, F4366].
Indications and Usage Memantine is used to manage moderate to severe Alzheimer's dementia [FDA label]. A more recent systemic review and meta-analysis [A177106] indicates that memantine is beneficial as a first line drug for the treatment of Alzheimer's dementia. Cholinesterase inhibitors may be added to memantine for further beneficial effects on behavioral symptoms and other symptoms of dementia [A177106].
Marketing Status approved; investigational
ATC Code N06DX01
DrugBank ID DB01043
KEGG ID D08174
MeSH ID D008559
PubChem ID 4054
TTD Drug ID D01JEU
NDC Product Code 72603-118; 24196-184; 60687-184; 65162-173; 0615-8192; 55154-4151; 62135-895; 0904-6506; 53746-169; 55111-597; 0904-6505; 65015-892; 53746-173; 60687-173; 62135-896; 65162-169; 70518-3297; 0615-8319; 55154-7637; 72603-119; 55111-596
UNII W8O17SJF3T
Synonyms Memantine | Memantin | 1,3-Dimethyl-5-aminoadamantane | 1-Amino-3,5-dimethyladamantane | Namenda | Ebixa | Memantine Hydrochloride | Axura | D-145 | D 145 | D145
Chemical Information
Molecular Formula C12H21N
CAS Registry Number 19982-08-2
SMILES CC12CC3CC(C1)(CC(C3)(C2)N)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dry mouth07.06.01.002--
Dry skin23.03.03.001--
Dysarthria17.02.08.001; 19.19.03.0010.000689%
Dysgeusia07.14.03.001; 17.02.07.003--
Dyskinesia17.01.02.0060.000846%
Dyspepsia07.01.02.001--
Dysphagia07.01.06.0030.001112%
Dyspnoea02.11.05.003; 22.02.01.0040.002732%
Dystonia17.01.03.0010.000266%-
Dysuria20.02.02.002--
Ear disorder04.03.01.001---
Ear pain04.03.01.003--
Ectropion06.06.04.001; 23.07.05.001---
Eczema23.03.04.006--
Electrocardiogram abnormal13.14.05.001---
Electrocardiogram QT prolonged13.14.05.004--
Electrolyte imbalance14.05.01.0020.000181%-
Embolism venous24.01.01.003---
Encephalopathy17.13.02.0010.000181%
Endocrine disorder05.09.01.001---
Epilepsy17.12.03.0020.000483%-
Epistaxis22.04.03.001; 24.07.01.005--
Eructation07.01.02.003--
Erythema multiforme10.01.03.015; 23.03.01.003--
Extrapyramidal disorder17.01.02.007--
Extrasystoles02.03.02.003---
Eye disorder06.08.03.001---
Eye pain06.08.03.002--
Facial paralysis17.04.03.0080.000121%-
Failure to thrive14.03.02.008; 18.04.01.003; 19.07.05.0010.000870%-
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 18 Pages